Protective Roles of Shilajit in Modulating Resistin,Adiponectin, and Cytokines in Rats with Non-alcoholic Fatty Liver Disease

Baran Ghezelbash; Nader Shahrokhi; Mohammad Khaksari; Gholamreza Asadikaram; Maryam Shahrokhi; Sara Shirazpour

doi:10.1007/s11655-022-3307-3

Your Location：

Home >

Browse articles >

Protective Roles of Shilajit in Modulating Resistin,Adiponectin, and Cytokines in Rats with Non-alcoholic Fatty Liver Disease

Original Article | Updated：2022-06-27

- Protective Roles of Shilajit in Modulating Resistin,Adiponectin, and Cytokines in Rats with Non-alcoholic Fatty Liver Disease
- Chinese Journal of Integrative Medicine Vol. 28, Issue 6, Pages: 531-537(2022)
- Affiliations：
  
  1.Physiology Research Center, Kerman University of Medical Sciences, Kerman (7616914115), Iran
  2.Endocrinology,and Metabolism Research Center, Kerman University of Medical Sciences, Kerman (7616914115), Iran
  3.Department of Biochemistry, School of Medicine, Kerman University of Medical Sciences, Kerman (7616914115), Iran
  4.Department of Medical Science, School of Dentistry, Shiraz University of Medical Sciences, Shiraz (713414336), Iran
  5.Department of Physiology and Pharmacology, Faculty of Medicine, Kerman University of Medical Sciences, Kerman (7616914115), Iran
- Author bio：
  
  Prof. Nader Shahrokhi, E-mail: nshahrokhisa@yahoo.com, nshahrokhi@kmu.ac.ir
- Funds：
- DOI：10.1007/s11655-022-3307-3
  CLC：
- Published：01 June 2022，
  
  Published Online：08 March 2022，
  
  Accepted：26 March 2021
Scan for full text
Baran Ghezelbash, Nader Shahrokhi, Mohammad Khaksari, et al. Protective Roles of Shilajit in Modulating Resistin,Adiponectin, and Cytokines in Rats with Non-alcoholic Fatty Liver Disease. [J]. Chinese Journal of Integrative Medicine 28(6):531-537(2022)
DOI：

Baran Ghezelbash, Nader Shahrokhi, Mohammad Khaksari, et al. Protective Roles of Shilajit in Modulating Resistin,Adiponectin, and Cytokines in Rats with Non-alcoholic Fatty Liver Disease. [J]. Chinese Journal of Integrative Medicine 28(6):531-537(2022) DOI： 10.1007/s11655-022-3307-3.

摘要

目的:

评价阿育吠陀药喜来芝对非酒精性脂肪性肝病(NAFLD)引起的血清细胞因子和脂肪因子变化的影响.

方法:

高脂饮食(HFD)建立脂肪肝模型12周后

将35只Wistar雄性大鼠随机分为5组

包括对照组(标准饮食)、Veh(HFD+空白对照)、高剂量喜来芝[H-Sh

HFD + 250 mg/(kg•d) 喜来芝]、低剂量喜来芝 [L-Sh

HFD + 150 mg/(kg•d) 喜来芝] 和吡格列酮 [HFD + 10 mg/(kg•d)吡格列酮组]

每组7只. 大鼠灌胃给药2周后

测定血清葡萄糖、胰岛素、白细胞介素 1β(IL-1β)、IL-6、IL-10、肿瘤坏死因子-α (TNF-α)、脂联素和抵抗素水平

并计算胰岛素抵抗指数 (HOMA-IR) .

结果:

NAFLD诱导后

喜来芝和吡格列酮给药均能明显升高血清IL-10水平

降低血清IL-1β、TNF-α水平 (

0.05) . 低、高剂量的喜来芝治疗可降低 NAFLD大鼠血清葡萄糖水平和 HOMA-IR (

0.05) . 两种剂量的喜来芝均可增加脂联素并降低血清抵抗素水平(

0.05).

结论:

喜来芝对NAFLD模型大鼠的保护作用可能是通过调节血清IL-1β、TNF-α、IL-10、脂肪因子和抵抗素水平

进而降低HOMA-IR.

Abstract

Objective:

To evaluate the effect of Shilajit

a medicine of Ayurveda

on the serum changes in cytokines and adipokines caused by non-alcoholic fatty liver disease (NAFLD).

Methods:

After establishing fatty liver models by feeding a high-fat diet (HFD) for 12 weeks

35 Wistar male rats were randomly divided into 5 groups

including control (standard diet)

Veh (HFD + vehicle)

high-dose Shilajit [H-Sh

HFD + 250 mg/(kg•d) Shilajit]

low-dose Shilajit [L-Sh

HFD + 150 mg/(kg•d) Shilajit]

and pioglitazone [HFD + 10 mg/(kg•d) pioglitazone] groups

7 rats in each group. After 2-week of gavage administration

serum levels of glucose

insulin

interleukin 1beta (IL-1β)

IL-6

IL-10

tumor necrosis factor-alpha (TNF-α)

adiponectin

and resistin were measured

and insulin resistance index (HOMA-IR) was calculated.

Results:

After NAFLD induction

the serum level of IL-10 significantly increased and serum IL-1β

TNF-α levels significantly decreased by injection of both doses of Shilajit and pioglitazone (

0.05). Increases in serum glucose level and homeostasis model of HOMA-IR were reduced by L-Sh and H-Sh treatment in NAFLD rats (

0.05). Both doses of Shilajit increased adiponectin and decreased serum resistin levels (

0.05).

Conclusion:

The probable protective role of Shilajit in NAFLD model rats may be via modulating the serum levels of IL-1β

TNF-α

IL-10

adipokine and resistin

and reducing of HOMA-IR.

关键词

Keywords

non-alcoholic fatty liver diseaseShilajitadipokinescytokinesglucoseinsulindietary supplementAyurvedic medicine

references

Effendi K, Harada K, Hashimoto E, Kage M, Koike K,Kondo F, et al. Pathological findings of NASH and NAFLD:for guidebook of NASH and NAFLD, 2015: The Japan Society of Hepatology. Hepatol Res 2017;47:3-10.

Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease—meta-analytic assessment of prevalence,incidence, and outcomes. Hepatology 2016;64:73-84.

Alam S, Mustafa G, Alam M, Ahmad N. Insulin resistance in development and progression of nonalcoholic fatty liver disease. World J Gastrointest Pathophysiol 2016;7:211.

Boden G, Homko C, Barrero CA, Stein TP, Chen X, Cheung P, et al. Excessive caloric intake acutely causes oxidative stress, GLUT4 carbonylation, and insulin resistance in healthy men. Sci Transl Med 2015;7:304-307.

Sears B, Perry M. The role of fatty acids in insulin resistance. Lipids Health Dis 2015;14:121.

Zhang Z, Wang J, Wang H. Correlation of blood glucose, serum chemerin and insulin resistance with NAFLD in patients with type 2 diabetes mellitus. Exper Ther Med 2018;15:2936-2940.

Utzschneider KM, Kahn SE. The role of insulin resistance in nonalcoholic fatty liver disease. J Clin Endocrinol Metab 2006;91:4753-4761.

Sekizkardes H, Chung ST, Chacko S, Haymond MW,Startzell M, Walter M, et al. Free fatty acid processing diverges in human pathologic insulin resistance conditions.J Clin Invest 2020;130. DOI: 10.1172/JCI135431http://doi.org/10.1172/JCI135431.

Matthews D, Hosker J, Rudenski A, Naylor B, Treacher D,Turner R. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419.

Fujii H, Imajo K, Yoneda M, Nakahara T, Hyogo H,Takahashi H, et al. HOMA-IR: an independent predictor of advanced liver fibrosis in nondiabetic non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2019;34:1390-1395.

Saltiel AR, Olefsky JM. Inflammatory mechanisms linking obesity and metabolic disease. J Clin Invest 2017;127:1-4.

Yki-Järvinen H, ed. Pathogenesis of nonalcoholic fatty liver disease (NAFLD). Chichester: John Wiley Sons, Ltd;2015:281-291.

Imam SK, ed. White adipose tissue: beyond fat storage.Obesity: Springer; 2016:1-12.

Jung UJ, Choi MS. Obesity and its metabolic complications:the role of adipokines and the relationship between obesity,inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease. Int J Mol Sci 2014;15:6184-6223.

Tarantino G, Savastano S, Colao A. Hepatic steatosis, low-grade chronic inflammation and hormone/growth factor/adipokine imbalance. World J Gastroenterol 2010;16:4773.

Stojsavljević S, Palĕić MG, Jukić LV, Duvnjak LS, Duvnjak M. Adipokines and proinflammatory cytokines, the key mediators in the pathogenesis of nonalcoholic fatty liver disease. World J Gastroenterol 2014;20:18070.

Jamali R, Hatami N, Kosari F. The correlation between serum adipokines and liver cell damage in non-alcoholic fatty liver disease. Hepat Mon 2016;16:e37412.

Matsuzawa Y. Adiponectin: a key player in obesity related disorders. Curr Pharm Des 2010;16:1896-1901.

Pant K, Gupta P, Damania P, Yadav AK, Gupta A, Ashraf A,et al. Mineral pitch induces apoptosis and inhibits proliferation via modulating reactive oxygen species in hepatic cancer cells. BMC Complement Altern Med 2016;16:148.

Thatte UM, Gogtay NJ. Traditional medicine: a review of work in India (2012–2017). Proc Indian Nat Sci Acad 2018;84:267-279.

Carrasco-Gallardo C, Guzmán L, Maccioni RB. Shilajit: a natural phytocomplex with potential procognitive activity. Int J Alzheimer's Dis 2012;2012:674142.

Ghaaazi Firozsalari F, Shahrokhi N, Khaksari Hadad M,Asadikaram G, Atashbar J. Effect of Shilajit on the levels of pro-inflammatory and anti-inflammation cytokines in hepatic injury in male rats. J Mazandaran Univer Med Sci 2018;27:1-13.

Verma A. Shilajitin cancer treatment: probable mode of action. Int J Pharm Biol Arch 2015;7:12-16.

Moghadari M, Rezvanipour M, Mehrabani M, Ahmadinejad M, Tajadini H, Hashempur MH. Efficacy of mummy on healing of pressure ulcers: a randomized controlled clinical trial on hospitalized patients in intensive care unit.Electronic Phys 2018;10:6140.

Trivedi N, Mazumdar B, Bhatt J, Hemavathi K. Effect of Shilajit on blood glucose and lipid profile in alloxan-induced diabetic rats. Indian J Pharmacol 2004;36:373.

Jafari M, Forootanfar H, Ameri A, Foroutanfar A, Adeli-Sardou M, Rahimi HR, et al. Antioxidant, cytotoxic and hyperalgesia-suppressing activity of a native Shilajit obtained from Bahr Aseman mountains. Pakistan J Pharm Sci 2019;32:2167-2173.

Masarone M, Rosato V, Dallio M, Gravina AG, Aglitti A,Loguercio C, et al. Role of oxidative stress in pathophysiology of nonalcoholic fatty liver disease. Oxid Med Cell Longev 2018;2018:9547613.

Deng XQ, Chen LL, Li NX. The expression of SIRT1 in nonalcoholic fatty liver disease induced by high-fat diet in rats. Liver Int 2007;27:708-715.

Khaksari M, Mahmmodi R, Shahrokhi N, Shabani M, Joukar S,Aqapour M. The effects of Shilajit on brain edema, intracranial pressure and neurologic outcomes following the traumatic brain injury in rat. Iran J Basic Med Sci 2013;16:858.

Pasarín M, Abraldes JG, Rodríguez-Vilarrupla A, La Mura V, García-Pagán JC, Bosch J. Insulin resistance and liver microcirculation in a rat model of early NAFLD. J Hepatol 2011;55:1095-1102.

Ghezelbash B, Shahrokhi N, Khaksari M, Ghaderi-Pakdel F,Asadikaram G. Hepatoprotective effects of Shilajit on high fat-diet induced non-alcoholic fatty liver disease (NAFLD) in rats. Hormone Mol Bio Clin Invest 2020;41.

Bhattacharaya S. Shilajit attenuates streptozotocin induced diabetes mellitus and decreases pancreatic islet superoxide dismutase activity in rats. Phytother Res 1995;9:41-44.

Kanikkannan N, Ramarao P, Ghosal S. Shilajit-induced potentiation of the hypoglycaemic action of insulin and inhibition of streptozotocin induced diabetes in rat.Phytother Res 1995;9:478-481.

Braunersreuther V, Viviani GL, Mach F, Montecucco F.Role of cytokines and chemokines in non-alcoholic fatty liver disease. World J Gastroenterol 2012;18:727.

Del Campo JA, Gallego P, Grande L. Role of inflammatory response in liver diseases: therapeutic strategies. World J Hepatol 2018;10:1.

Mirea AM, Tack CJ, Chavakis T, Joosten LA, Toonen EJ.IL-1 family cytokine pathways underlying NAFLD: towards new treatment strategies. Trends Mol Med 2018;24:458-471.

Li Z, Li Y, Zhang HX, Guo JR, Lam CWK, Wang CY, et al.Mitochondria-mediated pathogenesis and therapeutics for non-alcoholic fatty liver disease. Mol Nutrit Food Res 2019;63:1900043.

Niederreiter L, Tilg H. Cytokines and fatty liver diseases. Liver Res 2018;2:14-20.

Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 2001;280:E745-E751.

Fernandez-Real JM, Vayreda M, Richart C, Gutierrez C,Broch M, Vendrell J, et al. Circulating interleukin 6 levels, blood pressure, and insulin sensitivity in apparently healthy men and women. J Clin Endocrinol Metab 2001;86:1154-1159.

Shahrokhi N, Keshavarzi Z, Haddad MK, Amirafzali F,Dabiri S, Shahrokhi N. Protective effect of Mumiju against acetic acid-induced ulcerative colitis in rats. Avicenna J Phytomed 2018;8:457.

Mirza MA, Talegaonkar S, Ahmad FJ, Iqbal Z. A novel and multifunctional excipient for vaginal drug delivery. J Excipients Food Chem 2016;2:1119.

Wang Q, Ying J, Zou P, Zhou Y, Wang B, Yu D, et al.Effects of dietary supplementation of humic acid sodium and zinc oxide on growth performance, immune status antioxidant capacity weaned piglets. Animals 2020;10:2104.

van Rensburg CEJ, Naude PJ. Potassium humate inhibits complement activation and the production of inflammatory cytokines in vitro. Inflammation 2009;32:270-276.

Boutari C, Perakakis N, Mantzoros CS. Association of adipokines with development and progression of nonalcoholic fatty liver disease. Endocrinol Metab 2018;33:33-43.

Singh R, Moreno P, Hajjar RJ, Lebeche D. A role for calcium in resistin transcriptional activation in diabetic hearts. Sci Rep 2018;8:1-14.

Pagano C, Soardo G, Pilon C, Milocco C, Basan L, Milan G, et al. Increased serum resistin in nonalcoholic fatty liver disease is related to liver disease severity and not to insulin resistance. J Clin Endocrinol Metab 2006;91:1081-1086.

Adolph T, Grander C, Grabherr F, Tilg H. Adipokines and non-alcoholic fatty liver disease: multiple interactions. Intern J Molecular Sci 2017;18:1649.

Colica C, Abenavoli L. Resistin levels in non-alcoholic fatty liver disease pathogenesis. J Transl Inter Med 2018;6:52-53.

Finelli C, Tarantino G. What is the role of adiponectin in obesity related non-alcoholic fatty liver disease? World J Gastroenterol 2013;19:802-812.

Gamberi T, Magherini F, Modesti A, Fiaschi T. Adiponectin signaling pathways in liver diseases. Biomedicines 2018;6:52.

Ishtiaq SM, Rashid H, Hussain Z, Arshad MI, Khan JA.Adiponectin and PPAR: a setup for intricate crosstalk between obesity and non-alcoholic fatty liver disease. Rev Endoc Metab Disord 2019;20:253-261.

Xu A, Wang Y, Keshaw H, Xu LY, Lam KS, Cooper GJ.The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 2003;112:91-100.

Tilg H. The role of cytokines in non-alcoholic fatty liver disease. Digest Dis 2010;28:179-185.

More>

Views

Downloads

CSCD

Alert me when the article has been cited

Submit

Tools

Publicity Resources

Immunoregulatory and Anti-cancer Activities of Combination Treatment of Novel Four-Herb Formula and Doxorubicin in 4T1-Breast Cancer Bearing Mice

A Dietary Supplement Jinghuosu Ameliorates Reproductive Damage Induced by Tripterygium Glycosides

Modified Linggui Zhugan Decoction Ameliorates Glycolipid Metabolism and Inflammation via PI3K-Akt/mTOR-S6K1/AMPK-PGC-1α Signaling Pathways in Obese Type 2 Diabetic Rats

Intestinal Microecology: An Important Target for Chinese Medicine Treatment of Non-alcoholic Fatty Liver Disease

Electroacupuncture Delays Cartilage Degeneration by Modulating Nuclear Factor-κB Signaling Pathway

Related Author

No data

Related Institution

Li Dak Sum Yip Yio Chin R & D Centre for Chinese Medicine, The Chinese University of Hong Kong SAR

Australia International Research Centre for Chinese Medicine, School of Health and Biomedical Sciences, STEM College, RMIT University

Department of Chemical Pathology, The Chinese University of Hong Kong

State Key Laboratory of Research on Bioactivities and Clinical Applications of Medicinal Plants, The Chinese University of Hong Kong

Institute of Chinese Medicine, The Chinese University of Hong Kong

Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
Tel：010-62886827, 62877592 Fax：010-62874291
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰